Clinical Trials Results - National Cancer Institute

Skip to content

National Cancer Institute
U.S. National Institutes of Health | www.cancer.gov


	Clinical Trials Search Results

	Quick Links


	Director's Corner Dictionary of Cancer Terms NCI Drug Dictionary Funding Opportunities NCI Publications Advisory Boards and Groups Science Serving People Español

Questions about cancer?


	1-800-4-CANCER

	LiveHelp® online chat

	NCI Highlights


	Virtual and Standard Colonoscopy Both Accurate Denosumab May Help Prevent Bone Loss Past Highlights



Results: 1 -10 of 258 Show results per page	View Search Criteria \| Help With Results

	Title				Phase				Protocol IDs

	CryoSpray Ablation(tm)in Malignant Airway Disease to Determine Safety, and Tissue Effect in the Lung (ICE the MAD)				Phase IV				08-0106 NCT00748085
	Enbrel Versus Placebo With Radiation Therapy to Combat Fatigue and Cachexia				Phase III, Phase II				001-0015-211 NCT00127387
	Chemotherapy Drug Sensitivity Microculture (MiCK) Assay for Apoptosis				Phase III, Phase II				20050113 NCT00243685
	Docetaxel or Pemetrexed With or Without Cetuximab in Patients With Recurrent or Progressive Non-Small Cell Lung Cancer				Phase III				CP02-0452 NCT00095199
	Erlotinib or Placebo Following Chemoradiotherapy (Chemo/RT) in Stage III Non-Small Cell Lung Cancer (NSCLC)				Phase III				D-0410 NCT00153803
	Chemotherapy With or Without Bevacizumab in Treating Patients With Stage IB, Stage II, or Stage IIIA Non-Small Lung Cancer That Was Removed By Surgery				Phase III				ECOG-E1505 E1505, SWOG-E1505, CALGB-E1505, CAN-NCIC-E1505, NCCTG-E1505, NCT00324805
	Dietary Supplement in Treating Patients Who are Receiving Chemotherapy for Stage III or Stage IV Non-Small Cell Lung Cancer				Phase III				SFC-SV001 SFC-01-0150-0001-02-CM, SFC-01-0150-001, NCT00246727
	Study of NOV-002 in Combination With Chemotherapy to Treat Lung Cancer				Phase III				NOV002-C301 NCT00347412
	RADIANT: A Study of Tarceva After Surgery With or Without Adjuvant Chemotherapy in Non-Small Cell Lung Cancer (NSCLC) Patients Who Have Epidermal Growth Factor Receptor (EGFR) - Positive Tumors				Phase III				OSI-774-302 NCT00373425
	Cancer Vaccine Study for Unresectable Stage III Non-Small Cell Lung Cancer				Phase III				EMR 63325-001 NCT00409188


					1 2 3 4 Next >

| | | | | | | |

A Service of the National Cancer Institute